INCY News and Press, Incyte Corporation From 08/02/22

Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year g...

Incyte ( NASDAQ: INCY ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is $0.74 (-7.5% Y/Y) and the consensus Revenue Estimate is $818.25M (+15.9% Y/Y). Over the last 2 years, INCY has beaten EPS es...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. From 1/2/2016 to date, investing in all 50 stocks, equally weighted, would have produced a total return of 84.7%, a...

The stock market has been unpredictable and volatile all year long. All three major U.S. market indexes are in the red, and with economic problems still at the forefront of everyone's minds, no one knows when things will get better. Amid these issues, some stocks have performed surprisi...

Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...

CTI BioPharma's Pacritinib has been conditionally approved. It has critical differentiations with Incyte's Jakafi. While the potential is huge, cash and some data points are worrying signs. CTI BioPharma Corp. ( CTIC ) was granted accelerated approval of VONJO or pac...

The U.S. Food and Drug Administration (FDA) approved Incyte ( NASDAQ: INCY ) Opzelura cream to treat non-segmental vitiligo in patients 12 years of age and older. Incyte said Opzelura (ruxolitinib) is the first and only FDA-approved therapy for repigmentation...

Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation Fifty-two week data demonstrate ...

Incyte is outperforming the SP 500. Institutions are accumulating shares. My price target on INCY is $100. Incyte Corp. is Moving Higher Incyte Corporation ( INCY ) is a biopharmaceutical company that is outperforming the SP 500 index. There are several bullish i...

Four new VBR buy signals are discussed. I have become more cautious on the U.S. stock market's immediate direction, as the Federal Reserve continues to drain liquidity. When Wall Street turns bullish again, we should see an uptick in the number of companies to buy weekly, and much...